News: 2009

Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the developme...

New England Journal of Medicine Publishes a highly Successful Clinical Study by Leiden University Medical Center and ISA Pharmaceuticals B.V. with a therapeutic HPV vaccine in patients with premalignant vulv...

ORCA Therapeutics BV a biopharmaceutical company in the field of virotherapy, announces that it has obtained an exclusive license from VCN Biosciences SL of Gelida (Barcelona), Spain, to their T1 oncolytic a...

Syntarga B.V. announces that as of today patents have been granted for its proprietary SpaceLink Technology in Europe (EP 1370298 B1), the United States (US 7,223,837), India, China, New Zealand and Australi...

ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management te...

Three new small and medium enterprises (SMEs), Syncom, Synvolux Therapeutics and InteRNA Technologies, have joined the public-private partnership TI Pharma by participating in two new projects. The two proje...

FOR IMMEDIATE RELEASE Scientific & Corporate Leaders in Immunology, Tumor Immunology to be Honored at Cancer Research Institute 23rd Annual Awards Dinner 2009 Grace and Coley Award Winners Announced May 29,...

Bilthoven and Nijmegen (the Netherlands) - InteRNA Technologies B.V. and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for p...

ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management te...

Syntarga B.V. announced today that it has demonstrated strong and broad In Vivo Proof of Concept for Antibody-Drug Conjugates (ADCs) incorporating the Company's payload technology. The proprietary platform c...